Martin H. Voss, MD

Articles

Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

July 2nd 2024

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

July 2nd 2024

Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).

STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

July 2nd 2024

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

July 2nd 2024

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

June 25th 2024

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

June 25th 2024

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.

Extended Follow Up of KEYNOTE-B61

June 24th 2024

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

Evolving Treatment Standards in Non-Clear Cell RCC

June 24th 2024

Martin H. Voss, MD, and Moshe Ornstein, MD, engage in a professional discourse concerning the current treatment standards and the evolving therapeutic landscape for non-clear cell renal cell carcinoma (RCC).

KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

April 12th 2024

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

TKI Monotherapy Data in Non–Clear Cell RCC

April 12th 2024

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Overview of Non–Clear Cell RCC

April 5th 2024

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Clinical Insights on Belzutifan in Advanced RCC

April 5th 2024

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

March 29th 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

March 29th 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

March 22nd 2024

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

March 22nd 2024

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

March 15th 2024

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

March 15th 2024

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

March 8th 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

March 8th 2024

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.